In our previous work, it was suggested that IL-6 has a positive effect on hepatocytes in the liver with NAFLD by blocking trans-signaling IL-6 and activating non-canonical signaling pathway NF-kB in patients with type 2 diabetes mellitus [22]. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.